Browsing
     by title


0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

or enter first few letters:   
OK
Full Text
Peer Reviewed
See detailL'ostéoporose d'involution chez la femme
Reginster, Jean-Yves ULg; Devogelaer, J. P.; Kaufman, J. M. et al

in Revue Médicale de Liège (1999), 54(4), 335-40

Postmenopausal osteoporosis is now considered a major public health problem in aging women, due to the burden related to the consequent fractures. Over recent years, several pharmacological approaches ... [more ▼]

Postmenopausal osteoporosis is now considered a major public health problem in aging women, due to the burden related to the consequent fractures. Over recent years, several pharmacological approaches were developed for the prevention and treatment of osteoporosis. Besides regular physical exercise and calcium rich diet, calcium supplementation can be suggested to both genders, after seventy years as well as systematic vitamin D supplementation in order to cope with the frequent lack observed in our country. Hormone replacement therapy is the first choice in prevention of postmenopausal osteoporosis. Based on a careful evaluation of the needs of a postmenopausal woman as well as on the risk/benefit ratio derived from her individual risk factors, selective estrogen receptor modulators (raloxifene) or second generation bisphosphonates (alendronate) can be considered as alternative to estrogens. Due to its prohibitive cost, nasal calcitonin should be only considered for very specific cases. In osteoporosis confirmed by bone densitometry or by occurrence of fractures, bisphosphonate (alendronate) reduces subsequent fracture rate. Fluoride salts can, in some cases, improve spinal symptomatic osteoporosis. The use of etidronate, a molecule from the past, should be avoided as much as possible and, at any rate, strictly restricted to its legal indication including women with several vertebral crush fractures and severely decreased bone mineral density. [less ▲]

Detailed reference viewed: 44 (3 ULg)
Full Text
Peer Reviewed
See detailL’ostéoporose en questions : plus dure sera la chute
Reginster, Jean-Yves ULg

in Stethoscopie Magazine (1996), 63

Detailed reference viewed: 5 (1 ULg)
Full Text
Peer Reviewed
See detailL'osteoporose involutive de la femme: strategie therapeutique. Un point de vue actualise du Belgian Bone Club.
Kaufman, J M; Body, J J; Boonen, S et al

in Revue Médicale de Liège (2000), 55(5), 443-8

Osteoporosis is now considered as a major public health issue and a serious threat for the quality of life of elderly women. Several new compounds are currently marketed for the prevention and treatment ... [more ▼]

Osteoporosis is now considered as a major public health issue and a serious threat for the quality of life of elderly women. Several new compounds are currently marketed for the prevention and treatment of involutional osteoporosis in women. Therefore, it is important to offer to the practitioners pragmatic solutions to be used for the rational management of this disorder. This article is the result of a national consensus offering practical guidelines for the management of osteoporotic patients, based on the current published data. [less ▲]

Detailed reference viewed: 42 (1 ULg)
Full Text
Peer Reviewed
See detailL'ostéoporose passée sous microscope
Reginster, Jean-Yves ULg

in Actualité Médicale Belge (1986), 112

Detailed reference viewed: 11 (1 ULg)
Peer Reviewed
See detailL'ostéoporose postménopausique : un combat pour l'avenir
Lecart, MP; Denis, D; DEROISY, Rita ULg et al

in Contraception, Fertilité, Sexualité (1988), 2

Detailed reference viewed: 4 (1 ULg)
Peer Reviewed
See detailOstéoporose postménopausique: le point sur la thérapeutique
Reginster, Jean-Yves ULg

in Medisearch (1993), 73

Detailed reference viewed: 6 (2 ULg)
Peer Reviewed
See detailL'ostéoporose
Reginster, Jean-Yves ULg; Franchimont, P

in Reumatismo (1988), 31

Detailed reference viewed: 6 (1 ULg)
Peer Reviewed
See detailL'ostéoporose
Reginster, Jean-Yves ULg

in Medipractice Digest (1993)

Detailed reference viewed: 11 (2 ULg)
See detailL'ostéoporose: une maladie qui s'évite
Bruyère, Olivier ULg

Conference (2000, March 18)

Detailed reference viewed: 10 (2 ULg)
Full Text
See detailOsteoporosis
Reginster, Jean-Yves ULg; Bruyère, Olivier ULg; Cianferotti, Luisella et al

Book published by Future Medicine Ltd (2013)

Detailed reference viewed: 29 (7 ULg)
Full Text
Peer Reviewed
See detailOsteoporosis : the interest of a prospective vision
Gillet, Pierre ULg; Reginster-Haneuse, G; Reginster, Jean-Yves ULg

in Osteoporosis International (1996), 6(S1), 119

Detailed reference viewed: 3 (1 ULg)
Full Text
Peer Reviewed
See detailOsteoporosis : The interest of a prospective vision
Gillet, Pierre ULg; Gosset, Christiane ULg; Reginster, Jean-Yves ULg

in Calcified Tissue International (1997), 61

Detailed reference viewed: 18 (9 ULg)
Full Text
Peer Reviewed
See detailOsteoporosis and venous thromboembolism: a retrospective cohort study in the UK General Practice Research Database.
Breart, G.; Cooper, C.; Meyer, O. et al

in Osteoporosis International (2010), 21

In a retrospective cohort study using the General Practice Research Database (GPRD), there was a greater association of venous thromboembolism (VTE) in osteoporotic than in non-osteoporotic female ... [more ▼]

In a retrospective cohort study using the General Practice Research Database (GPRD), there was a greater association of venous thromboembolism (VTE) in osteoporotic than in non-osteoporotic female patients. No greater association was shown in treated patients with strontium ranelate or alendronate compared to untreated osteoporotic female patients. INTRODUCTION: We explored the risk of VTE in usual practice in osteoporotic and non-osteoporotic women with and without anti-osteoporotic treatment. METHODS: A retrospective study was conducted using the GPRD in the UK. The cohorts consisted of untreated osteoporotic women (N = 11,546), osteoporotic women treated with alendronate (N = 20,084), or strontium ranelate (N = 2,408), and a sample of non-osteoporotic women (N = 115,009). Cohorts were compared using a Cox proportional hazards regression model. RESULTS: There was a significantly increased relative risk for VTE in untreated osteoporotic women versus non-osteoporotic women (annual incidence 5.6 and 3.2 per 1,000 patient-years, respectively; relative risk 1.75 [95% confidence interval (CI), 1.09-1.84]). Results were confirmed using adjusted models. The annual incidences of VTE in osteoporotic patients treated with strontium ranelate and alendronate were 7.0 and 7.2 per 1,000 patient-years, respectively, with no significant difference between untreated and treated patients whatever the treatment. Adjusted hazard ratios for treated versus untreated osteoporotic women were 1.09 (95% CI, 0.60-2.01) for strontium ranelate and 0.92 (95% CI, 0.63-1.33) for alendronate. CONCLUSION: This study shows a greater association of VTE in osteoporotic compared to non-osteoporotic patients, but does not show any greater association in treated patients with strontium ranelate or alendronate compared to untreated osteoporotic patients. [less ▲]

Detailed reference viewed: 51 (2 ULg)
Full Text
Peer Reviewed
See detailOsteoporosis in daily clinical practice: prevalence of acute predictors in French postmenopausal women
Tancredi, Annalisa ULg; Bosio-Le goux, B.; Augendre-Ferrante, B. et al

in Osteoporosis International (2005, March), 16(Suppl.3), 108-109

Detailed reference viewed: 9 (2 ULg)
Full Text
Peer Reviewed
See detailOsteoporosis in patients taking selective serotonin reuptake inhibitors: a focus on fracture outcome
Bruyère, Olivier ULg; Reginster, Jean-Yves ULg

in Endocrine (in press)

Depression is one of the most important mental health problems and a leading cause of disability. Selective serotonin reuptake inhibitors (SSRIs) are considered as first-line therapy for the treatment of ... [more ▼]

Depression is one of the most important mental health problems and a leading cause of disability. Selective serotonin reuptake inhibitors (SSRIs) are considered as first-line therapy for the treatment of depressive symptoms among older adults because of their presumed favorable adverse effect profile. However, they could have deleterious effects on the bone. Evidence from longitudinal, crosssectional, and prospective cohort studies suggests that the use of antidepressants at therapeutic doses is associated with decreased bone mineral density and increased fracture risk. The association between SSRIs use and fracture risk could potentially differ depending on dose, exposure duration, time of exposure, age, or sex. However, the risk of fracture declined rapidly after discontinuation of use of SSRIs. The evidence now seems sufficient to consider adding SSRIs to the list of medications that contribute to osteoporosis. In practice, assessment of risk factor for osteoporosis or fractures could be made taking into account age, gender, duration, and severity of depression, length of SSRI treatments, and other concurrent risk factors. [less ▲]

Detailed reference viewed: 16 (10 ULg)
Full Text
Peer Reviewed
See detailOsteoporosis in the European Union : a compendium of country-specific reports
Svedbom, A; Hernlund, E; Ivergard, M et al

in Archives of Osteoporosis (2013), 8(137), 1-218

This report describes epidemiology, burden, and treatment of osteoporosis in each of the 27 countries of the European Union (EU27). INTRODUCTION: In 2010, 22 million women and 5.5 million men were ... [more ▼]

This report describes epidemiology, burden, and treatment of osteoporosis in each of the 27 countries of the European Union (EU27). INTRODUCTION: In 2010, 22 million women and 5.5 million men were estimated to have osteoporosis in the EU; and 3.5 million new fragility fractures were sustained, comprising 620,000 hip fractures, 520,000 vertebral fractures, 560,000 forearm fractures and 1,800,000 other fractures. The economic burden of incident and prior fragility fractures was estimated at euro 37 billion. Previous and incident fractures also accounted for 1,180,000 quality-adjusted life years lost during 2010. The costs are expected to increase by 25 % in 2025. The majority of individuals who have sustained an osteoporosis-related fracture or who are at high risk of fracture are untreated and the number of patients on treatment is declining. The aim of this report was to characterize the burden of osteoporosis in each of the EU27 countries in 2010 and beyond. METHODS: The data on fracture incidence and costs of fractures in the EU27 were taken from a concurrent publication in this journal (Osteoporosis in the European Union: Medical Management, Epidemiology and Economic Burden) and country specific information extracted. RESULTS: The clinical and economic burden of osteoporotic fractures in 2010 is given for each of the 27 countries of the EU. The costs are expected to increase on average by 25 % in 2025. The majority of individuals who have sustained an osteoporosis-related fracture or who are at high risk of fracture are untreated and the number of patients on treatment is declining. CONCLUSIONS: In spite of the high cost of osteoporosis, a substantial treatment gap and projected increase of the economic burden driven by aging populations, the use of pharmacological prevention of osteoporosis has decreased in recent years, suggesting that a change in healthcare policy concerning the disease is warranted. [less ▲]

Detailed reference viewed: 17 (2 ULg)
Full Text
Peer Reviewed
See detailOsteoporosis in the very elderly
Halkin, V; Bruyère, Olivier ULg; Reginster, Jean-Yves ULg

in Medicographia (2002), 24(4), 316-321

Detailed reference viewed: 11 (4 ULg)
Full Text
See detailOsteoporosis patients demonstrate high levels of vitamin D depletion
Bruyère, Olivier ULg

E-print/Working paper (2008)

Detailed reference viewed: 13 (0 ULg)
Full Text
Peer Reviewed
See detailOsteoporosis prevalence estimates for men: variation based on normative data
Gourlay, Margaret L; Richy, Florent; Garrett, Joanne et al

in Arthritis and Rheumatism (2003, September), 48(number 9 (suppl.)), 298

Detailed reference viewed: 3 (0 ULg)